EUCTR2009-016962-10-IT进行中（未招募）1 期
First Line Dose-Dense Chemotherapy With Docetaxel, Cisplatin, Folinic Acid and 5- Fluorouracil plus Panitumumab in Patients With Locally Advanced or Metastatic Cancer of the Stomach or Gastro-Esophageal Junction: A Phase II Multicentre Trial - GOIRC 02/2009
GRUPPO ONCOLOGICO ITALIANO DI RICERCA0 个研究点目标入组 52 人开始时间: 2010年1月19日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 52
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Histologically confirmed advanced carcinoma of the stomach or oesophago-gastric junction 2. Patients with locally advanced inoperable tumors 3. Measurable lesions according to RECIST criteria (version 1.1) 4. A previous adjuvant chemotherapy for gastric cancer is authorized provided that it was finished minimum 6 months before the inclusion in this protocol and if the patient is considered free from adverse events related to adjuvant chemotherapy. 5. Age ≥ 18, and ≤ 75 years 6. ECOG Performance status 0-1 7. Hematological examination : Neutrophilic count ≥ 1.5 X 109 / l, Platelets ≥ 100 X 109 /l, Hemoglobin ≥ 10 g / dl ASAT/ALAT ≤ 1,5 X ULN , Alkaline Phosphatases < 2,5 ULN Bilirubin ≤ 1,5 X ULN Clearance creatinine ≥ 60 ml/min Magnesium ≥ lower limit of normal. Calcium ≥ lower limit of normal 8. Written informed consen
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Uncontrolled central nervous system metastases. 2. Past (less than 10 years) or current history of malignant neoplasms, except for curatively treated carcinoma in situ of the cervix or basal and squamous cell carcinoma of the skin. 3. Participation to another clinical study within 4 weeks before inclusion in this study 4. Concomitant antineoplastic treatment. 5. Previous use in adjuvant setting of more than 400 mg/m? (total cumulated dose) cisplatin 6. Known deficiency in DPD or allergy to one or more drugs of the study 7. Uncontrolled angina pectoris or myocardial infarction < 6 weeks before beginning of the chemotherapy 8. Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) 1 year before enrollment/randomization 9. History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan. 10. Other concurrent serious diseases that may interfere with planned treatment. 11. Uncontrolled infectious disease. 12. Impossibility to assure an adequate follow-up due to psychological, familial, social and/or geographic reasons. 13. Subject pregnant or breast feeding, or planning to become pregnant within 6 months after the end of treatment. Subject (male or female) is not willing to use highly effective methods of contraception (per institutional standard) during treatment and for 6 months (male or female) after the end of treatment.
研究者
相似试验
已完成
1 期
PhaseI/II trial of chemotherapy with docetaxel, CDDP and 5-Fluorouracil followed by chemoradiotherapy with CDDP and 5-Fluorouracil in patients with locally advanced esophageal cancer.esophageal cancerJPRN-UMIN000003546Department of Surgical Oncology, Division of Clinical and Experimental Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University60
进行中（未招募）
1 期
eoadjuvant, sequential chemotherapy with docetaxel followed by Fluorouracil, Epirubicin, and Cyclophosphamid every 3 weeks - genome wide expression analysis for identification of a predictive gene signature in patients with primary breast cancer - EXPRESSIOEligible will be only females between 18 - 70 years of age, suffering from histologically confirmed primary breast cancer, nodal status positive or negative, phase cT2, cT3, or cT4 including inflammatory disease. Metastatic disease is excluded. All patients will be treated with 3 cycles Docetaxel and 3 cycles FEC.MedDRA version: 14.1Level: PTClassification code 10006201Term: Breast cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10021974Term: Inflammatory breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10006202Term: Breast cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10006200Term: Breast cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-006381-29-DEniversitätsmedizin Mainz200
已完成
不适用
the phase I study of chemotherapy with Docetaxel+Nedaplatin+5-FU(DNF) to esophageal cancerStageII,III,IV non-resective esophageal cancer and recurrece ofesophageal cancerJPRN-UMIN000005083Gunma University Graduate School Department of General Surgical Science18
已完成
不适用
eo adjuvant chemotherapy by Docetaxel + S-1 for resentable gasric cabcergastric cancerJPRN-UMIN000015632Department of Frontier Surgery, Graduate school of Medicine, Chiba University20
已完成
2 期
Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by chemoradiotherapy concurrent with fractionated administration of high-dose cisplatin for patients with locally advanced squamous cell carcinoma of the head and neckocally advanced head and neck cancerJPRN-UMIN000024686ational Cancer Center Hospital East48